---
title: "IMVT-1402 Phase 2 topline results in refractory rheumatoid arthritis announced — DecisionGateway"
description: "IMVT-1402 Phase 2 topline results in refractory rheumatoid arthritis announced"
canonical_url: "https://dgw.tmarket.io/events/01a1d950-dac0-7478-9975-03fc8a553889"
meta:
  "og:description": "IMVT-1402 Phase 2 topline results in refractory rheumatoid arthritis announced"
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "IMVT-1402 Phase 2 topline results in refractory rheumatoid arthritis announced — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

**Event**/Publication

**Completed**

# **IMVT-1402 Phase 2 topline results in refractory rheumatoid arthritis announced**

## **Source**

> IMVT-1402의 난치성 류마티스관절염 Period 2 탑라인 결과 발표.

*hmsecresearch · Telegram [ Open post](https://t.me/hmsecresearch/6167)*

## **Not established**

- Time is the source publish date, not the event itself

## **Related events**

Same kind only, ranked by embedding similarity to this record.

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/events/01a1d950-dac0-7478-9975-03fc8a553889#webpage","@type":"WebPage","description":"IMVT-1402 Phase 2 topline results in refractory rheumatoid arthritis announced","name":"IMVT-1402 Phase 2 topline results in refractory rheumatoid arthritis announced — DecisionGateway","url":"https://dgw.tmarket.io/events/01a1d950-dac0-7478-9975-03fc8a553889","breadcrumb":{"@id":"https://dgw.tmarket.io/events/01a1d950-dac0-7478-9975-03fc8a553889#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/events/01a1d950-dac0-7478-9975-03fc8a553889"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/events/01a1d950-dac0-7478-9975-03fc8a553889#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Feed","item":"https://dgw.tmarket.io/feed","position":2},{"@type":"ListItem","name":"IMVT-1402 Phase 2 topline results in refractory rheumatoid arthritis announced","position":3}]}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.